Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide

Study Purpose

The overarching goal of this study is to examine the acute vasoreactive response to both inhaled nitric oxide and inhaled epoprostenol across both traditionally and non-traditionally interrogated phenotypes in PH, and to further characterize the relationship of vasoreactivity to disease severity and PH phenotype.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.

Searching Both is inclusive of interventional and observational studies.

Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - mPAP ≥ 21mmHg, PAWP ≤ 25mmHg, and PVR ≥3 WU.
  • - Classified as WHO group I-III pulmonary hypertension.

Exclusion Criteria:

  • - WHO group IV and V pulmonary hypertension.
  • - Patients who are on baseline pulmonary vasodilator medications.
  • - Severe aortic or mitral valve disease.
  • - Patients who are pregnant.
  • - Left ventricular ejection fraction of <35% - Patients who are hospitalized as inpatients at the time of RHC.
- Patients with systolic blood pressure <90mmHg or mean arterial pressure of < 60mmHg

Trial Details

Trial ID:

This trial id was obtained from, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.


Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 4
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Brigham and Women's Hospital
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Aaron B Waxman, MD
Principal Investigator Affiliation Brigham and Women's Hospital
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Overall Status Recruiting
Countries United States

The disease, disorder, syndrome, illness, or injury that is being studied.

Pulmonary Hypertension
Arms & Interventions


Active Comparator: Inhaled Nitric Oxide

Vasodilator testing will be performed with inhaled nitric oxide

Experimental: Inhaled Epoprostenol

Vasodilator testing will be performed with inhaled epoprostenol


Drug: - Vasodilator testing (Inhaled Nitric Oxide)

Right heart catheterization with vasodilator testing with each arms' associated agent will be performed

Drug: - Vasodilator testing (Inhaled Epoprostenol)

Right heart catheterization with vasodilator testing with each arms' associated agent will be performed

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Brigham and Women's Hospital, Boston, Massachusetts




Brigham and Women's Hospital

Boston, Massachusetts, 02115

Site Contact

Aaron B Waxman, MD, PhD


For more information, please contact PHA at and refer to the terms of service below.

Submit Feedback

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation in a clinical trial or study.